Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on ...

Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth expectations for its Wegovy obesity drug in the key U.S. market. Shares were down ...

Medical bottles and a syringe are seen with the Novo Nordisk logo displayed on a screen in the background.

Wegovy, a weight loss drug, is gaining popularity for its effectiveness, but experts emphasize that it's most successful when combined with a healthy ...